United States Biotechnology & Medical Research

X4 Pharmaceuticals Inc (XFOR)

Track

Over the past 90 days, X4 Pharmaceuticals Inc. recorded three insider transactions, all consisting of sales by Chief Financial Officer David Kirske. These sales totaled approximately $109,249. This activity follows the company's May 2026 earnings report, where it reported a 20% earnings beat, amid a 90-day stock price decline of 8.6%.
Ticker: XFOR Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for X4 Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 30 Jun 2026
Value US$1,981,909.65 | Price 398.20 | Shares 13,796 (-49.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-01 2026-06-30 S Sale
KIRSKE DAVID

Chief Financial Officer

Officer
13,796 -49.9%
398.20
US$1,981,910 		13,796 -49.9% 398.20 US$1,981,910
2026-05-13 2026-05-12 S Sale
KIRSKE DAVID

Chief Financial Officer

Officer
92,282 -32.4%
436.16
US$2,624,350 		92,282 -32.4% 436.16 US$2,624,350
2026-05-12 2026-05-12 PrS Proposed sale
David Kirske

Officer

Officer
88,957
55.23
US$1,838,301 		88,957 55.23 US$1,838,301
2025-10-27 2025-10-23 B Purchase
4.0
Craig Adam R

Executive Chairman

Executive Director
86,206 +29.7%
2.90
US$249,997 		86,206 +29.7% 2.90 US$249,997
2025-05-20 2025-05-16 PP Planned purchase
Baldry Mark

Chief Commercial Officer

Officer
1,032 +4.2%
2.48
US$2,561 		1,032 +4.2% 2.48 US$2,561
2025-01-27 2025-01-24 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
29,159 -23.7%
0.45
US$13,241 		29,159 -23.7% 0.45 US$13,241
2025-01-27 2025-01-24 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
76,473 -6.6%
0.45
US$34,719 		76,473 -6.6% 0.45 US$34,719
2025-01-27 2025-01-24 PlS Planned sale
Arbet-Engels Christophe

Chief Medical Officer

Officer
11,624 -45.0%
0.45
US$5,284 		11,624 -45.0% 0.45 US$5,284
2025-01-27 2025-01-24 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
22,258 -4.3%
0.45
US$10,094 		22,258 -4.3% 0.45 US$10,094
2025-01-27 2025-01-24 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
74,773 -100.0%
0.45
US$33,947 		74,773 -100.0% 0.45 US$33,947
2025-01-24 2025-01-24 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
76,473
0.52
US$39,766 		76,473 0.52 US$39,766
2025-01-24 2025-01-24 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
22,258
0.52
US$11,574 		22,258 0.52 US$11,574
2025-01-24 2025-01-24 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
24,828
0.52
US$12,911 		24,828 0.52 US$12,911
2025-01-24 2025-01-24 PrS Proposed sale
Arbet-Engels Christophe

Officer

Officer
11,624
0.52
US$6,044 		11,624 0.52 US$6,044
2025-01-24 2025-01-24 PrS Proposed sale
Baldry Mark

Officer

Officer
29,159
0.52
US$15,163 		29,159 0.52 US$15,163
2025-02-14 2024-11-15 PP Planned purchase Baldry Mark

Chief Commercial Officer

Officer
13,404 +11.6%
0.34
US$4,598 		13,404 +11.6% 0.34 US$4,598
2024-11-19 2024-11-15 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
31,897 -3.1%
0.39
US$12,583 		31,897 -3.1% 0.39 US$12,583
2024-11-15 2024-11-15 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
31,897
0.41
US$13,078 		31,897 0.41 US$13,078
2024-10-16 2024-10-15 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
31,897 -3.0%
0.56
US$17,926 		31,897 -3.0% 0.56 US$17,926
2024-10-15 2024-10-15 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
31,897
0.56
US$17,862 		31,897 0.56 US$17,862
2025-01-24 2024-10-07 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
74,773
0.52
US$38,882 		74,773 0.52 US$38,882
2024-10-08 2024-10-07 PlS Planned sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
76,920 -16.5%
0.56
US$43,306 		76,920 -16.5% 0.56 US$43,306
2024-10-08 2024-10-07 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
11,127 -18.7%
0.58
US$6,506 		11,127 -18.7% 0.58 US$6,506
2024-10-08 2024-10-07 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
239,436 -18.5%
0.55
US$131,522 		239,436 -18.5% 0.55 US$131,522
2024-10-08 2024-10-07 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
230,645 -100.0%
0.55
US$126,901 		230,645 -100.0% 0.55 US$126,901
2024-10-08 2024-10-07 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
67,695 -13.0%
0.57
US$38,329 		67,695 -13.0% 0.57 US$38,329
2024-10-07 2024-10-07 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
67,695
0.64
US$43,095 		67,695 0.64 US$43,095
2024-10-07 2024-10-07 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
230,645
0.64
US$146,829 		230,645 0.64 US$146,829
2024-10-07 2024-10-07 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
239,436
0.64
US$152,425 		239,436 0.64 US$152,425
2024-10-07 2024-10-07 PrS Proposed sale
Baldry Mark

Officer

Officer
11,127
0.64
US$7,083 		11,127 0.64 US$7,083
2024-10-07 2024-10-07 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
76,920
0.64
US$48,967 		76,920 0.64 US$48,967
2024-09-11 2024-09-09 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
2,642 -0.9%
0.66
US$1,738 		2,642 -0.9% 0.66 US$1,738
2024-09-09 2024-09-09 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
2,642
0.65
US$1,728 		2,642 0.65 US$1,728
2025-02-14 2024-05-17 PP Planned purchase Baldry Mark

Chief Commercial Officer

Officer
21,646 +23.0%
0.68
US$14,654 		21,646 +23.0% 0.68 US$14,654
2024-03-11 2024-03-11 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
14,235
0.90
US$12,812 		14,235 0.90 US$12,812
2024-03-11 2024-03-11 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
52,500
0.90
US$47,250 		52,500 0.90 US$47,250
2024-03-11 2024-03-11 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
15,409
0.90
US$13,868 		15,409 0.90 US$13,868
2024-03-11 2024-03-11 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
49,678
0.90
US$44,710 		49,678 0.90 US$44,710
2024-03-11 2024-03-11 S Sale
1.5
Ragan Paula

President and CEO

Executive Director
49,678 -6.1%
0.88
US$43,856 		49,678 -6.1% 0.88 US$43,856
2024-03-11 2024-03-11 S Sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
52,500 -100.0%
0.88
US$46,347 		52,500 -100.0% 0.88 US$46,347
2024-03-11 2024-03-11 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
15,409 -5.0%
0.88
US$13,591 		15,409 -5.0% 0.88 US$13,591
2024-03-11 2024-03-11 S Sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
14,235 -5.7%
0.88
US$12,552 		14,235 -5.7% 0.88 US$12,552
2024-02-12 2024-02-12 PrS Proposed sale
1.9
Taveras Arthur

Officer

Officer
787
0.97
US$763 		787 0.97 US$763
2024-02-12 2024-02-12 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
27,721
0.97
US$26,889 		27,721 0.97 US$26,889
2024-02-12 2024-02-12 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
3,683
0.97
US$3,573 		3,683 0.97 US$3,573
2024-02-12 2024-02-12 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
21,695
0.97
US$21,044 		21,695 0.97 US$21,044
2024-02-12 2024-02-12 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
27,721 -34.6%
1.01
US$27,973 		27,721 -34.6% 1.01 US$27,973
2024-02-12 2024-02-12 S Sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
787 -0.3%
1.01
US$793 		787 -0.3% 1.01 US$793
2024-02-12 2024-02-12 S Sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
3,683 -1.2%
1.01
US$3,709 		3,683 -1.2% 1.01 US$3,709
2024-02-12 2024-02-12 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
21,695 -2.6%
1.01
US$21,892 		21,695 -2.6% 1.01 US$21,892
2023-11-03 2023-11-03 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
39,906
0.80
US$32,096 		39,906 0.80 US$32,096
2023-11-03 2023-11-03 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
39,906 -4.6%
0.90
US$35,915 		39,906 -4.6% 0.90 US$35,915
2023-11-03 2023-11-01 PlS Planned sale
1.9
Taveras Arthur

Chief Scientific Officer

Officer
67,695 -21.4%
0.73
US$49,417 		67,695 -21.4% 0.73 US$49,417
2023-11-03 2023-11-01 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
67,695 -17.9%
0.73
US$49,417 		67,695 -17.9% 0.73 US$49,417
2023-11-03 2023-11-01 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
230,645 -74.2%
0.73
US$168,371 		230,645 -74.2% 0.73 US$168,371
2023-11-03 2023-11-01 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
199,531 -18.5%
0.73
US$145,658 		199,531 -18.5% 0.73 US$145,658
2023-11-03 2023-11-01 PlS Planned sale
Baldry Mark

Chief Commercial Officer

Officer
10,257 -29.4%
0.73
US$7,488 		10,257 -29.4% 0.73 US$7,488
2023-11-01 2023-11-01 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
199,531
0.79
US$157,848 		199,531 0.79 US$157,848
2023-11-01 2023-11-01 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
67,695
0.79
US$53,553 		67,695 0.79 US$53,553
2023-11-01 2023-11-01 PrS Proposed sale
1.9
Taveras Arthur

Affiliate
67,695
0.79
US$53,553 		67,695 0.79 US$53,553
2023-11-01 2023-11-01 PrS Proposed sale
Baldry Mark

Officer

Officer
10,257
0.79
US$8,144 		10,257 0.79 US$8,144
2023-11-01 2023-11-01 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
230,645
0.79
US$182,463 		230,645 0.79 US$182,463
2023-09-12 2023-09-08 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
2,642 -1.8%
1.25
US$3,300 		2,642 -1.8% 1.25 US$3,300
2023-09-08 2023-09-08 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
2,642
1.24
US$3,276 		2,642 1.24 US$3,276
2023-08-22 2023-08-18 B Purchase
0.6
WYZGA MICHAEL S
Non-Executive Director
25,000 +48.4%
1.20
US$29,875 		25,000 +48.4% 1.20 US$29,875
2023-08-11 2023-08-10 S Sale
2.3
Stewart Murray

Interim Chief Medical Officer

Executive Director
130,056 -47.0%
1.06
US$137,859 		130,056 -47.0% 1.06 US$137,859
2023-07-05 2023-06-30 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
2,641 -3.2%
1.89
US$4,991 		2,641 -3.2% 1.89 US$4,991
2023-07-05 2023-06-30 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
464 -0.3%
1.89
US$877 		464 -0.3% 1.89 US$877
2023-06-26 2023-06-23 PlS Planned sale
1.5
Ragan Paula

President and CEO

Executive Director
6,724 -1.2%
1.92
US$12,910 		6,724 -1.2% 1.92 US$12,910
2023-06-26 2023-06-23 PlS Planned sale
1.5
Mostafa Adam S.

Chief Financial Officer

Officer
5,417 -6.1%
1.93
US$10,455 		5,417 -6.1% 1.93 US$10,455
2023-06-26 2023-06-23 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
857 -0.6%
1.93
US$1,654 		857 -0.6% 1.93 US$1,654
2023-06-23 2023-06-23 PrS Proposed sale
2.3
DiBiase Mary

Officer

Officer
857
1.93
US$1,652 		857 1.93 US$1,652
2023-06-23 2023-06-23 PrS Proposed sale
1.5
Ragan Paula

Officer

Officer
6,724
1.92
US$12,930 		6,724 1.92 US$12,930
2023-06-23 2023-06-23 PrS Proposed sale
1.5
Mostafa Adam S.

Officer

Officer
5,417
1.96
US$10,617 		5,417 1.96 US$10,617
2023-06-16 2023-06-15 PlS Planned sale
2.3
DiBiase Mary

Chief Operating Officer

Officer
857 -0.6%
2.23
US$1,911 		857 -0.6% 2.23 US$1,911
Explore more

More insider trading research around X4 Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America